microRNAs Orchestrate Pathophysiology of Breast Cancer Brain Metastasis: Advances in Therapy
Brain metastasis (BM) predominantly occurs in triple-negative (TN) and epidermal growth factor 2 (HER2)-positive breast cancer (BC) patients, and currently, there is an unmet need for the treatment of these pa...
t Jennifer R. Diamond Triple-negative breast cancer (TNBC) is an aggressive subtype defined by lack of hormone receptor expression and non-amplified HER2. Adavosertib (AZD1775) is a potent, small-molecule, ATP-competitive inhibitor of the Wee1 kinase that potentiates the activity of many DNA-damaging chemotherapeutics and is currently in clinical development for multiple indications. The purpose of this study was to investigate the combination of AZD1775 and capecitabine/5FU in preclinical TNBC models. TNBC cell lines were treated with AZD1775 and 5FU and cellular proliferation was assessed in real-time using IncuCyt...
Condition: Breast Cancer Interventions: Drug: Pyrotinib; Drug: Temozolomide Injection; Drug: SHR-1316; Drug: Bevacizumab; Drug: Cisplatin/Carboplatin Sponsor: Fudan University Not yet recruiting
Conclusions: TLC demonstrated promising effects and tolerable safety in HER2+MBC, even in patients with BM, providing a theoretical basis for clinical practice.Clinical Trial Registration:ClinicalTrials.gov, Identifier: NCT04001634.
CONCLUSIONS: The study provides a comprehensive and individual evaluation of the risk factors that could support the design of screening tools and interventional trials for early detection of BCBM. PMID: 32110283 [PubMed - as supplied by publisher]
CONCLUSIONS: This single-centre series of consecutive patients with brain metastases from breast cancer, treated with SRS, had a similar overall survival compared with previous studies of SRS. TNBC and ER+/HER2- histology, metastatic volumes>10 cm3 and progressive extracranial disease at the time of SRS were associated with worse survival. PMID: 32131980 [PubMed - as supplied by publisher]
CONCLUSIONS: We show an increase of BM over time whilst the time span from primary BC to BM is unchanged supports earlier findings that adjuvant treatments have little preventive function. Time from extra cranial recurrence to BM was prolonged with one year. Patients with TNBC or more advance extent of BM had the shortest survival with BM. PMID: 32145571 [PubMed - as supplied by publisher]
For patients with breast cancer brain metastases, new prognostic factors are identified and incorporated into an updated Graded Prognostic Assessment (Breast GPA). Over decades, treatment patterns have changed and survival has improved. Median survival for patients in the best prognostic group now exceeds 3 years. Furthermore, these data suggest HER2-targeted therapies improve outcomes for these patients. The Breast GPA facilitates clinical decision-making, end-of-life care and appropriate stratification of future clinical trials.
Future Oncology, Ahead of Print.
This study aimed to validate whether the recently-proposed prognostic grading system, initial brain metastasis velocity (iBMV), is applicable to breast cancer patients receiving stereotactic radiosurgery (SRS). We focused particularly on whether this grading system is useful for patients with all molecular types, i.e., positive versus negative for EsR, PgR and HER2.Methods and materialsThis was an institutional review board-approved, retrospective cohort study using our database, prospectively accumulated at three gamma knife institutes, during the 20-year-period since 1998. We excluded patients for whom the day of primary...
ConclusionsDisease progression occurred intracranially more often than extracranially following resection of a solitary BCBM. In ER+ patients, postoperative hormonal therapy was associated with longer OS. Postoperative HER2-targeted therapy did not show survival benefit in HER2+ patients. These results should be validated in larger cohorts.